Nurix Therapeutics’ stock posted a dramatic pre-market gain after the company announced a comprehensive global collaboration with Roche to co-develop and co-commercialize bexobrutideg, Nurix’s oral Bruton’s tyrosine kinase (BTK) degrader. The agreement covers multiple therapeutic areas, including malignant hematology, immunology, and neurology.
Under the terms disclosed, Nurix will receive $700 million in upfront cash and could collect up to an additional $2.3 billion in development, regulatory, and commercial milestone payments. Development expenditures will be shared between the partners, with Nurix responsible for 40% and Roche covering 60%. Should the program reach the market, profits will be divided equally between the two companies.
The timing of the deal was notable given the clinical data that had already been generated for bexobrutideg. The asset produced an 83% objective response rate and a median progression-free survival of 22.1 months in a cohort of heavily pretreated chronic lymphocytic leukemia patients, results that the companies cited in connection with the partnership.
Analysts had generally been constructive on Nurix ahead of the announcement. Firms including Stifel, Needham, Oppenheimer, and Piper Sandler held Buy-equivalent recommendations on the shares, and the street maintained a consensus 12-month price target near $30. That backdrop reflected recognition of bexobrutideg’s commercial potential, although market participants had not widely anticipated a collaboration on this scale and with the financial terms announced.
The pre-market surge lifted NRIX to $21.97, closing in on its 52-week high of $22.50. That rally stood in sharp contrast to the broader U.S. equity market during the same session, where major indices were in decline: the S&P 500 fell 2.6%, the Dow Jones Industrial Average dropped 1.4%, and the NASDAQ slid 4.2%, signaling heavy selling pressure overall.
Notably, peer companies in the targeted protein degradation and related biotechnology space did not mirror Nurix’s strength. Names such as Kymera Therapeutics and Arvinas were trading lower on the day, underscoring that NRIX’s move was driven by company-specific corporate news rather than a sector-wide tailwind.
Taken together, the Roche partnership represents a significant de-risking milestone for Nurix: it brings substantial non-dilutive capital, access to a major global commercialization partner, and external validation of bexobrutideg’s profile. Those elements combined to produce one of the most sizable single-session gains in the company’s trading history, even as the broader market faced material headwinds.
Market snapshot and comparatives
- NRIX near 52-week high at $21.97 following announcement.
- Major U.S. indices declined: S&P 500 -2.6%, Dow -1.4%, NASDAQ -4.2%.
- Peers Kymera Therapeutics and Arvinas traded lower, indicating the rally was company-specific.
What the agreement means in practical terms
- Immediate non-dilutive financing: $700 million upfront to Nurix.
- Potential upside: up to $2.3 billion in additional milestone payments tied to development, regulatory, and commercial achievements.
- Shared development economics: Nurix covers 40% of development costs while Roche covers 60%.
- Profit sharing: net profits will be split 50/50 if commercialized.
These contract structures combined with the clinical response data were central to investor enthusiasm and explain the outsized market reaction for Nurix on a day when equities broadly sold off.